Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06444737

Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia

Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia for Cesarean Sections : A Randomized Controlled Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
Mongi Slim Hospital · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

A prospective, bicentric, randomized, double-blind controlled study including parturients scheduled for elective caesarean delivery under spinal anaesthesia and randomized and assigned to one of the two groups: Group O ondansetron : receiving Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia Group C control : receiving IV normal saline 5 ml (control group) 5 min before spinal anesthesia OBJECTIVE : To evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section.

Detailed description

Spinal anesthesia is the most common anesthetic technique used for Caesarean sections. However, it is not denied from complications. Post-dural puncture headache is a major complication of spinal anesthesia, with an incidence ranging from 1.5% to 36%. OBJECTIVE : To evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section. the investigators conducted a prospective, bicentric, randomized, double-blind controlled study over a period of 07 months from November 2023 to june 2024. the investigators included in the study all parturients: * Aged between 18-45 years * ASA 2 * Between 37 and 41 weeks of gestation * scheduled for elective caesarean delivery under spinal anaesthesia * To be delivered by unscheduled caesarean section whose indication does not involve a vital maternal or fetal emergency, according to the Lucas' classification. The eligible parturients were randomly assigned to two groups through block randomization using computerized random numbers. were assigned to one of the two parallel groups to receive either : * Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia : Group O (Ondansetron) * Or IV normal saline 5 ml (control group) 5 min before spinal anesthesia : Group C (control)

Conditions

Interventions

TypeNameDescription
DRUGIntravenous ondansetronIntravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
DRUGIntravenous normal salineIntravenous normal saline 5 ml (control group) 5 min before spinal anesthesia

Timeline

Start date
2023-11-30
Primary completion
2024-06-30
Completion
2024-08-30
First posted
2024-06-06
Last updated
2024-06-06

Locations

1 site across 1 country: Tunisia

Source: ClinicalTrials.gov record NCT06444737. Inclusion in this directory is not an endorsement.